November 6, 2014. The NBC investigation of Essure has raised very important questions regarding the safety of the Essure permanent birth control device.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Testimony at FDA Risk Communication Advisory Committee on Fish Consumption
November 3, 2014. NCHR states that most consumers don’t want to have a long list of exactly what kind of fish to eat and what to avoid. If pregnant and breastfeeding women have avoided fish for themselves and for their young children, it’s because the messages they were getting were confusing. Come up with phrases that are easy to remember and and messages that are straightforward.
Read More »NCHR Comments on Social Media Platforms Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices
October 29, 2014. NCHR states that patients and consumers increasingly rely on social media and the internet as sources of health and medical information that influence their decisions to seek medical care, and clarity is important.
Read More »NCHR Testimony at FDA Joint Public Advisory Committee Meeting on Chantix
October 16, 2014. NCHR strongly urges the FDA to keep the black box warning to protect patients and that you strengthen rather than weaken that boxed warning. And, since the meta analyses are fatally flawed, the FDA should delete the misleading meta-analyses info from the Chantix label.
Read More »NCHR Comments on FDA Safety and Innovation Act Action Plan
October 21, 2014. NCHR strongly supports inclusion of separate analysis of safety and effectiveness for demographic subgroups in clinical trials for drugs and devices. It is essential that methodologically sound data about how drugs and devices work in these groups be conducted and made publicly available.
Read More »